Faculty Opinions recommendation of LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression.
Year: 2023
Type: peer-review
Author: Holden Maecker
Institutions: Stanford Medicine, Stanford University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4389135961